Senolytic research has long been stalled by a practical problem: most candidate compounds are experimental, toxic at effective doses, or unavailable outside a lab. A dietary supplement that selectively kills senescent cells would change that calculus, which is why this mouse work deserves attention, along with a firm reminder that the evidence is animal-only. The investigators identified a biochemical weak point in senescent cells: the reactivity of cysteine residues across their proteome is altered relative to healthy cells, likely reflecting the redox shifts that accompany the senescent state. They then screened for agents that exploit this difference and found vanadyl sulfate, a vanadium salt sold as a supplement, selectively eliminates senescent cells. In aged mice, treatment reportedly improved multiple age-related conditions and extended lifespan. Placing this in context, cysteine-based redox chemistry is a genuinely new angle compared with the better-known senolytic strategies, such as BCL-2 family inhibition with navitoclax or the dasatinib-plus-quercetin combination, which target anti-apoptotic survival pathways. A proteome-wide chemical vulnerability could, in principle, be broader and more tunable. The caution is considerable, though. Vanadium compounds have a long history in human trials as insulin-mimetic agents, and those studies reported gastrointestinal side effects and unresolved questions about accumulation in tissue and long-term toxicity. A dose that is senolytic in mice may not translate to a safe human dose, and nothing here supports taking vanadyl sulfate off the shelf. Mouse lifespan findings also frequently fail to replicate across strains and laboratories. I would rate this as a promising mechanistic advance for the senolytic field, valuable mainly for the target it exposes rather than for the supplement itself. Human safety and efficacy data would be required before it carries any practical meaning for adults.